Migraine Common in Women With Macromastia, Headache
via HealthDayTUESDAY, Feb. 17, 2026 -- Most women with macromastia and headache pursuing reduction surgery screen positive for migraine, according to a study published online Feb. 2 in Cephalalgia Reports.
Kristyn Spera Pocock, M.D., from the Wake Forest University School of Medicine in Winston-Salem, North Carolina, and colleagues conducted an observational study to characterize headache features in women with macromastia undergoing reduction. Participants were aged 18 years and older and had four or more headache-days/month.
Baseline headaches were frequent and disabling for the 34 participants (median, 10 days/months; mean pain intensity, 6.2/10; mean Migraine Disability Assessment, 49.8). Forty percent had allodynia; 56 percent screened high-risk for obstructive sleep apnea. Ninety-one percent screened positive for migraine, and 100 percent reported red-flag features. Significant improvements were seen in headache frequency (incidence rate ratio, 0.23), pain intensity, (mean, −3.0), disability (mean, −32.9), allodynia (mean, −2.1), and obstructive sleep apnea risk (odds ratio, 0.19) postoperatively, and were sustained through 19 to 28 months.
"Headache is a common complaint in women with macromastia, or enlarged breast tissue, pursuing breast reduction surgery, yet it's often not evaluated in depth," Pocock said in a statement. "Our findings suggest we may be missing migraine in this population, and that matters for diagnosis, treatment, and quality of life."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-02-18 13:38
Read more
- FDA Expands Tater Tot Recall Tied to Possible Plastic Contamination
- Overweight, Obesity Remained Highly Prevalent in U.S. Youths in 2024
- U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
- Couples Who Do This One Thing Feel More Satisfied And Secure Together
- FDA Approves Filkri (filgrastim-laha), a Biosimilar to Neupogen
- Exercise Can Reduce Depression, Anxiety Symptoms
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions